Related Experiment Videos
Abstract:
Two separate periods of intensive research, with a 25-year hiatus after the advent of the sulfonamides, have resulted in two good, but imperfect, antimeningococcal vaccines--against serogroups A and C. Neither is recommended for routine use, but both have been effective in halting epidemics. Lack of an effective group B immunogen remains the major obstacle to the control of meningococcal disease.